Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction

Yasunori Mizuguchi, Akira Miyajima, Takeo Kosaka, Takako Asano, Tomohiko Asano, Masamichi Hayakawa

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Purpose: The current study was done to determine whether atorvastatin, the HMGCoA (3-hydroxy-3-methylglutaryl CoA) reductase inhibitor, could decrease renal transforming growth factor-β (TGF-β) levels in unilateral ureteral obstruction (UUO) and concomitantly affect renal tissue damage in UUO. Materials and Methods: Atorvastatin (20 mg/kg) was administered to rats 1 day prior to UUO and every day thereafter. Kidneys were harvested at day 14 after UUO. Tissue TGF-β was measured by bioassay using mink lung epithelial cells. Renal tubular proliferation and apoptosis were detected by immunostaining proliferating cell nuclear antigen and polyclonal antisingle strand DNA antibody, respectively. Fibrosis was assessed by measuring collagen deposition with trichrome stained slides. Interstitial leukocyte was detected by immunostaining CD45. Results: TGF-β bioassay showed that the obstructed kidney in the control group contained significantly higher TGF-β than the unobstructed kidney in the control group (mean ± SD 79.1 ± 48.5 vs 28.7 ± 13.7 pg/mg tissue) and atorvastatin significantly decrease tissue TGF-β in the obstructed kidney (53.4 ± 37.0 pg/mg tissue). Immunostaining polyclonal antisingle strand DNA antibody demonstrated that the obstructed kidney in the control group has significantly more tubular apoptosis than the unobstructed counterpart (4.8 ± 2.8 vs 2.1 ± 1.2 nuclei per high power field) and atorvastatin significantly decreased renal tubular apoptosis in the obstructed kidney (1.1 ± 0.7 nuclei per high power field). In addition, immunostaining proliferating cell nuclear antigen showed that the obstructed kidney in the atorvastatin group had significantly more renal tubular proliferation than the obstructed kidney in the control group (48.7 ± 20.8 vs 17.3 ± 10.6 per high power field). Control obstructed kidney showed significantly more fibrosis, which was also blunted by atorvastatin. Conclusions: Atorvastatin significantly decreases tissue TGF-β, resulting in a decrease in tubular damage and interstitial fibrosis. This suggests that atorvastatin is a promising agent for preventing renal tubular damage in UUO.

Original languageEnglish
Pages (from-to)2456-2459
Number of pages4
JournalJournal of Urology
Volume172
Issue number6 I
DOIs
Publication statusPublished - 2004 Dec
Externally publishedYes

Fingerprint

Ureteral Obstruction
Kidney
Transforming Growth Factors
Control Groups
Fibrosis
Proliferating Cell Nuclear Antigen
Apoptosis
Atorvastatin Calcium
Biological Assay
Renal Agents
Hydroxymethylglutaryl CoA Reductases
Mink
Antibodies
DNA

Keywords

  • Apoptosis
  • Atorvastatin
  • Kidney
  • Transforming growth factor beta
  • Ureteral obstruction

ASJC Scopus subject areas

  • Urology

Cite this

Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction. / Mizuguchi, Yasunori; Miyajima, Akira; Kosaka, Takeo; Asano, Takako; Asano, Tomohiko; Hayakawa, Masamichi.

In: Journal of Urology, Vol. 172, No. 6 I, 12.2004, p. 2456-2459.

Research output: Contribution to journalArticle

Mizuguchi, Y, Miyajima, A, Kosaka, T, Asano, T, Asano, T & Hayakawa, M 2004, 'Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction', Journal of Urology, vol. 172, no. 6 I, pp. 2456-2459. https://doi.org/10.1097/01.ju.0000138473.38447.f0
Mizuguchi, Yasunori ; Miyajima, Akira ; Kosaka, Takeo ; Asano, Takako ; Asano, Tomohiko ; Hayakawa, Masamichi. / Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction. In: Journal of Urology. 2004 ; Vol. 172, No. 6 I. pp. 2456-2459.
@article{48dd4c6381dd4627bf2aa89db3ab2d11,
title = "Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction",
abstract = "Purpose: The current study was done to determine whether atorvastatin, the HMGCoA (3-hydroxy-3-methylglutaryl CoA) reductase inhibitor, could decrease renal transforming growth factor-β (TGF-β) levels in unilateral ureteral obstruction (UUO) and concomitantly affect renal tissue damage in UUO. Materials and Methods: Atorvastatin (20 mg/kg) was administered to rats 1 day prior to UUO and every day thereafter. Kidneys were harvested at day 14 after UUO. Tissue TGF-β was measured by bioassay using mink lung epithelial cells. Renal tubular proliferation and apoptosis were detected by immunostaining proliferating cell nuclear antigen and polyclonal antisingle strand DNA antibody, respectively. Fibrosis was assessed by measuring collagen deposition with trichrome stained slides. Interstitial leukocyte was detected by immunostaining CD45. Results: TGF-β bioassay showed that the obstructed kidney in the control group contained significantly higher TGF-β than the unobstructed kidney in the control group (mean ± SD 79.1 ± 48.5 vs 28.7 ± 13.7 pg/mg tissue) and atorvastatin significantly decrease tissue TGF-β in the obstructed kidney (53.4 ± 37.0 pg/mg tissue). Immunostaining polyclonal antisingle strand DNA antibody demonstrated that the obstructed kidney in the control group has significantly more tubular apoptosis than the unobstructed counterpart (4.8 ± 2.8 vs 2.1 ± 1.2 nuclei per high power field) and atorvastatin significantly decreased renal tubular apoptosis in the obstructed kidney (1.1 ± 0.7 nuclei per high power field). In addition, immunostaining proliferating cell nuclear antigen showed that the obstructed kidney in the atorvastatin group had significantly more renal tubular proliferation than the obstructed kidney in the control group (48.7 ± 20.8 vs 17.3 ± 10.6 per high power field). Control obstructed kidney showed significantly more fibrosis, which was also blunted by atorvastatin. Conclusions: Atorvastatin significantly decreases tissue TGF-β, resulting in a decrease in tubular damage and interstitial fibrosis. This suggests that atorvastatin is a promising agent for preventing renal tubular damage in UUO.",
keywords = "Apoptosis, Atorvastatin, Kidney, Transforming growth factor beta, Ureteral obstruction",
author = "Yasunori Mizuguchi and Akira Miyajima and Takeo Kosaka and Takako Asano and Tomohiko Asano and Masamichi Hayakawa",
year = "2004",
month = "12",
doi = "10.1097/01.ju.0000138473.38447.f0",
language = "English",
volume = "172",
pages = "2456--2459",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6 I",

}

TY - JOUR

T1 - Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction

AU - Mizuguchi, Yasunori

AU - Miyajima, Akira

AU - Kosaka, Takeo

AU - Asano, Takako

AU - Asano, Tomohiko

AU - Hayakawa, Masamichi

PY - 2004/12

Y1 - 2004/12

N2 - Purpose: The current study was done to determine whether atorvastatin, the HMGCoA (3-hydroxy-3-methylglutaryl CoA) reductase inhibitor, could decrease renal transforming growth factor-β (TGF-β) levels in unilateral ureteral obstruction (UUO) and concomitantly affect renal tissue damage in UUO. Materials and Methods: Atorvastatin (20 mg/kg) was administered to rats 1 day prior to UUO and every day thereafter. Kidneys were harvested at day 14 after UUO. Tissue TGF-β was measured by bioassay using mink lung epithelial cells. Renal tubular proliferation and apoptosis were detected by immunostaining proliferating cell nuclear antigen and polyclonal antisingle strand DNA antibody, respectively. Fibrosis was assessed by measuring collagen deposition with trichrome stained slides. Interstitial leukocyte was detected by immunostaining CD45. Results: TGF-β bioassay showed that the obstructed kidney in the control group contained significantly higher TGF-β than the unobstructed kidney in the control group (mean ± SD 79.1 ± 48.5 vs 28.7 ± 13.7 pg/mg tissue) and atorvastatin significantly decrease tissue TGF-β in the obstructed kidney (53.4 ± 37.0 pg/mg tissue). Immunostaining polyclonal antisingle strand DNA antibody demonstrated that the obstructed kidney in the control group has significantly more tubular apoptosis than the unobstructed counterpart (4.8 ± 2.8 vs 2.1 ± 1.2 nuclei per high power field) and atorvastatin significantly decreased renal tubular apoptosis in the obstructed kidney (1.1 ± 0.7 nuclei per high power field). In addition, immunostaining proliferating cell nuclear antigen showed that the obstructed kidney in the atorvastatin group had significantly more renal tubular proliferation than the obstructed kidney in the control group (48.7 ± 20.8 vs 17.3 ± 10.6 per high power field). Control obstructed kidney showed significantly more fibrosis, which was also blunted by atorvastatin. Conclusions: Atorvastatin significantly decreases tissue TGF-β, resulting in a decrease in tubular damage and interstitial fibrosis. This suggests that atorvastatin is a promising agent for preventing renal tubular damage in UUO.

AB - Purpose: The current study was done to determine whether atorvastatin, the HMGCoA (3-hydroxy-3-methylglutaryl CoA) reductase inhibitor, could decrease renal transforming growth factor-β (TGF-β) levels in unilateral ureteral obstruction (UUO) and concomitantly affect renal tissue damage in UUO. Materials and Methods: Atorvastatin (20 mg/kg) was administered to rats 1 day prior to UUO and every day thereafter. Kidneys were harvested at day 14 after UUO. Tissue TGF-β was measured by bioassay using mink lung epithelial cells. Renal tubular proliferation and apoptosis were detected by immunostaining proliferating cell nuclear antigen and polyclonal antisingle strand DNA antibody, respectively. Fibrosis was assessed by measuring collagen deposition with trichrome stained slides. Interstitial leukocyte was detected by immunostaining CD45. Results: TGF-β bioassay showed that the obstructed kidney in the control group contained significantly higher TGF-β than the unobstructed kidney in the control group (mean ± SD 79.1 ± 48.5 vs 28.7 ± 13.7 pg/mg tissue) and atorvastatin significantly decrease tissue TGF-β in the obstructed kidney (53.4 ± 37.0 pg/mg tissue). Immunostaining polyclonal antisingle strand DNA antibody demonstrated that the obstructed kidney in the control group has significantly more tubular apoptosis than the unobstructed counterpart (4.8 ± 2.8 vs 2.1 ± 1.2 nuclei per high power field) and atorvastatin significantly decreased renal tubular apoptosis in the obstructed kidney (1.1 ± 0.7 nuclei per high power field). In addition, immunostaining proliferating cell nuclear antigen showed that the obstructed kidney in the atorvastatin group had significantly more renal tubular proliferation than the obstructed kidney in the control group (48.7 ± 20.8 vs 17.3 ± 10.6 per high power field). Control obstructed kidney showed significantly more fibrosis, which was also blunted by atorvastatin. Conclusions: Atorvastatin significantly decreases tissue TGF-β, resulting in a decrease in tubular damage and interstitial fibrosis. This suggests that atorvastatin is a promising agent for preventing renal tubular damage in UUO.

KW - Apoptosis

KW - Atorvastatin

KW - Kidney

KW - Transforming growth factor beta

KW - Ureteral obstruction

UR - http://www.scopus.com/inward/record.url?scp=8644242286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8644242286&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000138473.38447.f0

DO - 10.1097/01.ju.0000138473.38447.f0

M3 - Article

VL - 172

SP - 2456

EP - 2459

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6 I

ER -